Motility News

WASHINGTON — In this exclusive video, Joseph Murray, MD, of the Mayo Clinic in Rochester, Minn., shares some insight on research presented at Digestive Disease Week about checkpoint inhibitor-induced diarrhea.

WASHINGTON — Patients with constipation who received prucalopride did not show an increased risk for major cardiovascular events, according to research presented at Digestive Disease Week.

WASHINGTON — More than one-third of patients hospitalized for constipation are readmitted within 90 days, and clinical rather than demographic factors were key predictors of readmission, according to research presented at Digestive Disease Week.

WASHINGTON — In this exclusive industry perspective from Digestive Disease Week 2018, Mike Nedham, product strategy lead in GI at Shire, discusses the company’s new initiatives in gastroenterology and hepatology health care and advocacy.

WASHINGTON — A bile acid sequestrant improved heartburn and regurgitation when paired with a proton pump inhibitor in patients with persistent GERD, according to the results of a phase 2b trial presented at Digestive Disease Week.

WASHINGTON — Alfuzosin, an alpha1 receptor antagonist, helped decrease anal pressure in women with constipation, according to data from a study presented at Digestive Disease Week.

Evoke Pharma has submitted a new drug application to the FDA for Gimoti, a nasal-spray formulation of the dopamine-receptor antagonist metoclopramide for management of diabetic gastroparesis symptoms in women, the company announced in a press release.

WASHINGTON — Laparoscopic Nissen fundoplication was superior to medical therapy among carefully selected patients with heartburn refractory to proton pump inhibitors, according to new research.

WASHINGTON — Electrical stimulation of the lower esophageal sphincter using the Endostim LES Stimulation System was safe and effective for treating carefully selected patients with persistent GERD symptoms despite proton pump inhibitor therapy, according to interim data from the LESS-GERD registry presented here.

WASHINGTON — Itopride appeared to improve symptoms in patients with functional dyspepsia, including those with both postprandial distress and epigastric pain syndromes, according to a presenter here.